Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | SELE | P16581 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886702 | 0.82 | MAPT (0.50) | MAPTRAB9AHPGDIKBKBKDM4E | |
| SCHEMBL618697 | 0.77 | KMT2A (0.56) | MAPTRAB9AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL641107 | 0.76 | MAPT (0.56) | MAPTHPGDIKBKBKDM4ESMN1; SMN2 | |
| SCHEMBL30309931 | 0.75 | CYP1A2 (0.49) | MAPTIKBKBKDM4EALDH1A1GAA | |
| SCHEMBL9853825 | 0.75 | CYP1A2 (0.49) | MAPTIKBKBKDM4EALDH1A1GAA | |
| SCHEMBL25908122 | 0.74 | BTK (0.54) | MAPTRAB9AHPGDIKBKBSMN1; SMN2 | |
| SCHEMBL28816979 | 0.74 | KDM4E (0.50) | MAPTRAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL4741898 | 0.73 | USP2 (0.52) | MAPTHPGDKDM4EALDH1A1GAA | |
| SCHEMBL4085591 | 0.73 | RAB9A (0.63) | MAPTRAB9AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL18355733 | 0.73 | KMT2A (0.68) | MAPTRAB9AHPGDKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| CN-1341098-A | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER AG (US) | 2002-03-20 | — | — | CN | disclosed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2180/4885RAB9A 1936/4885HPGD 2652/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | MAPT 2754/4885RAB9A 1400/4885HPGD 2749/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2299/4885RAB9A 2093/4885HPGD 2745/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2299/4885RAB9A 2093/4885HPGD 2745/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPT 2474/4885RAB9A 2639/4885HPGD 2852/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | MAPT 2928/4885RAB9A 1099/4885HPGD 2546/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | MAPT 2490/4885RAB9A 2215/4885HPGD 2758/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPT 2299/4885RAB9A 2093/4885HPGD 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.